With Bydureon's U.S. Approval, Amylin Extends Exenatide Franchise Twice delayed by "complete response" letters, the drug's approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
Korea Takes Steps To Consolidate Domestic Pharma Industry And Reward Innovation Korea's Ministry of Health and Welfare announced goals to reshape its pharma industry as it aims to be among the top seven pharma-strong countries by 2020.
Verastem Joins The Public Markets With A Strong IPO Verastem IPO'd at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.
Pfizer Bases Bosutinib U.S. Filing On One Single Arm Phase II Trial FDA accepts NDA for dual Srk and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML on a positive news day for Pfizer. Meanwhile, review in front-line CML is pending in Europe.
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx's Nexavar .
CMS' Long-Awaited Medicaid AMP Rule Seeks To Clarify Uncertainties In Affordable Care Act's Definition A proposed rule on the calculation of average manufacturer price issued Jan. 27 addresses numerous complex issues for the pharmaceutical industry in its 160 pages, including a proposal that manufacturers report AMP based on their actual sales to retail community pharmacies or to wholesalers for drugs distributed to retail community pharmacies.
